What does POMBILITI + OPFOLDA — total revenues mean?

This metric represents the total net sales generated from the commercialization of the POMBILITI and OPFOLDA therapeutic combination. It reflects the market adoption and revenue-generating performance of this specific rare-disease treatment regimen within the company's product portfolio. Monitoring this figure provides insight into the commercial trajectory and growth contribution of the company's specialized enzyme replacement or gene therapy offerings.

BioMarin Pharmaceuticals (BMRN) POMBILITI + OPFOLDA — Total revenues

Screener

Other product segments

VOXZOGO

$252.53M+14.1%

VIMIZIM

$194.37M-9.8%

NAGLAZYME

$135.26M+5.0%

PALYNZIQ

$135.17M+27.6%

GALAFOLD

$105.75M—

BRINEURA

$51.37M+5.5%

ALDURAZYME

$43.54M-22.9%

KUVAN

$24.44M-9.6%

ROCTAVIAN

$11.71M+27.3%

Royalty and other revenues

$5.32M-57.2%

Similar metrics at other companies

SNDAResident revenue — Total revenues

$108.43M+36.8%

ASSTOther revenue — Total revenues

$43K+514%

ALN

ALNYRoyalty revenue — Total revenues

$71.67M+79.3%

HContra revenue — Total revenues

-$17M-13.3%

FTAIMaintenance revenue — Total revenues

$30.6M-38.3%

FTAIOther revenue — Total revenues

$6.21M+19,923%

Other financials

Income statement

See full

Revenue$989.7M+19.9%

Gross profit$786.9M+16.5%

Operating income$110.9M-59.9%

Net income$44.8M-81.4%

EPS (diluted)$0.23-81.3%

Balance sheet

See full

Cash & equivalents$874.0M-28.0%

Total debt$4.2B+598%

Total equity$6.3B+4.9%

Total assets$11.7B+57.2%

Cash flow

See full

Operating cash flow$168.1M-9.3%

CapEx$28.8M+68.5%

Free cash flow$139.3M-17.2%

Valuation

See full

Market cap$11.58B-0.6%

Enterprise value$14.89B+34.9%

P/E32.2×-34.7×

P/S3.4×-0.4×

Profitability

See full

Gross margin76.1%-3.4pp

Operating margin19.9%+7.2pp

Net margin16.8%+5.1pp

FCF margin21.7%-1.0pp

Returns & leverage

See full

Return on equity9.1%+2.8pp

Debt / equity0.7×+0.6×

Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 4:14 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001048477-26-000016

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
GALAFOLD(1)	105,748	—	105,748	—
BRINEURA	51,370	48,692	98,474	89,054
ALDURAZYME	43,539	56,437	80,281	105,414
POMBILITI + OPFOLDA(1)	30,258	—	30,258	—
KUVAN	24,444	27,034	48,324	52,170
ROCTAVIAN	11,713	9,199	14,349	19,709
Total net product revenues	984,393	812,982	1,744,471	1,547,626
Royalty and other revenues	5,315	12,428	11,445	22,929

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's POMBILITI + OPFOLDA — total revenues?: BioMarin Pharmaceuticals (BMRN) reported POMBILITI + OPFOLDA — total revenues of $30.26M in Q2 2026.
What does POMBILITI + OPFOLDA — total revenues mean?: This metric represents the total net sales generated from the commercialization of the POMBILITI and OPFOLDA therapeutic combination. It reflects the market adoption and revenue-generating performance of this specific rare-disease treatment regimen within the company's product portfolio. Monitoring this figure provides insight into the commercial trajectory and growth contribution of the company's specialized enzyme replacement or gene therapy offerings.